

Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an International Verapamil SR-Trandolapril (INVEST) substudy S. Bangalore, F. H. Messerli, J. D. Cohen, P. H. Bacher, P. Sleight, G. Mancina, P. Kowey, Q. Zhou, A. Champion and C. J. Pepine *Am Heart J* (2008) 156; 241-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18657652

Effects of erythropoietin after an acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III) A. M. Belonje, A. A. Voors, W. H. van Gilst, S. D. Anker, R. H. Slart, R. A. Tio, F. Zijlstra and D. J. van Veldhuisen *Am Heart J* (2008) 155; 817-22

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18440327

Aldosterone and long-term outcome after myocardial infarction: A substudy of the french nationwide Observatoire sur la Prise en charge hospitaliere, l'Evolution a un an et les caracteristiques de patients presentant un infarctus du myocarde avec ou sans onde Q (OPERA) study F. Beygui, G. Montalescot, E. Vicaut, S. Rouanet, E. Van Belle, C. Baulac, A. Degrandisart and J. Dallongeville *Am Heart J* (2009) 157; 680-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19332195

Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study Y. Bi, R. Gao, A. Patel, S. Su, W. Gao, D. Hu, D. Huang, L. Kong, W. Qi, Y. Wu, Y. Yang and F. Turnbull *Am Heart J* (2009) 157; 509-16 e1

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19249422

Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials) E. S. Brilakis, J. A. de Lemos, C. P. Cannon, S. D. Wiviott, S. A. Murphy, D. A. Morrow, M. S. Sabatine, S. Banerjee, M. A. Blazing, R. M. Califf and E. Braunwald *Am J Cardiol* (2008) 102; 552-8

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18721511

Alpha-linolenic acid and risk of nonfatal acute myocardial infarction H. Campos, A. Baylin and W. C. Willett *Circulation* (2008) 118; 339-45

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18606916

Challenging doctors' lifelong habits may be good for their patients: oxygen therapy in acute myocardial infarction N. Danchin and D. Chemla *Heart* (2009) 95; 176-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19029170

Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells R. E. Eid, D. A. Rao, J. Zhou, S. F. Lo, H. Ranjbaran, A. Gallo, S. I. Sokol, S. Pfau, J. S. Pober and G. Tellides *Circulation* (2009) 119; 1424-32

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19255340

Pericardial fat, intrathoracic fat, and measures of left ventricular structure and function: the Framingham Heart Study C. S. Fox, P. Gona, U. Hoffmann, S. A. Porter, C. J. Salton, J. M. Massaro, D. Levy, M. G. Larson, R. B. D'Agostino, Sr., C. J. O'Donnell and W. J. Manning *Circulation* (2009) 119; 1586-91

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19289634

Ten-year all-cause mortality in presumably healthy subjects on lipid-lowering drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort) V. Gardette, V. Bongard, J. Dallongeville, D. Arveiler, A. Bingham, J. B. Ruidavets, P. Amouyel, B. Haas, P. Ducimetiere and J. Ferrieres *Am J Cardiol* (2009) 103; 381-6

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19166693

Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction G. Heusch, A. Skyschally, P. Gres, P. van Caster, D. Schilawa and R. Schulz *Eur Heart J* (2008) 29; 2265-75

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18621770

B-type natriuretic peptide infusions in acute myocardial infarction R. J. Hillock, C. M. Frampton, T. G. Yandle, R. W. Troughton, J. G. Lainchbury and A. M. Richards *Heart* (2008) 94; 617-22

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17639095

A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE) I. K. Jang, N. J. Weissman, M. H. Picard, M. R. Zile, V. Pettigrew, S. Shen, J. Tatsuno, M. G. Hibberd, D. Tzivoni and F. J. Wackers *Am Heart J* (2008) 155; 113 e1-8

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18082500

Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon Y. Kawai, K. Hisamatsu, H. Matsubara, K. Dan, S. Akagi, K. Miyaji, M. Munemasa, Y. Fujimoto, K. F. Kusano and T. Ohe *Eur Heart J* (2009) 30; 765-72

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19276198

Effect of previous treatment with statins on outcome of patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention E. I. Lev, R. Kornowski, H. Vaknin-Assa, I. Ben-Dor, D. Brosh, I. Teplitsky, S. Fuchs, A. Battler and A. Assali *Am J Cardiol* (2009) 103; 165-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19121430

Hormone therapy and risk of myocardial infarction: a national register study E.

Lokkegaard, A. H. Andreasen, R. K. Jacobsen, L. H. Nielsen, C. Agger and O. Lidegaard *Eur Heart J* (2008) 29; 2660-8
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18826989
High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis A. Lotfi, M. J. Schweiger, G. R. Giugliano, S. A. Murphy and C. P. Cannon *Am Heart J* (2008) 155; 954-8
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18440347
Heritability and genome-wide linkage in US and Australian twins identify novel genomic regions controlling chromogranin a: implications for secretion and blood pressure D. T. O'Connor, G. Zhu, F. Rao, L. Taupenot, M. M. Fung, M. Das, S. K. Mahata, M. Mahata, L. Wang, K. Zhang, T. A. Greenwood, P. A. Shih, M. G. Cockburn, M. G. Ziegler, M. Stridsberg, N. G. Martin and J. B. Whitfield *Circulation* (2008) 118; 247-57
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18591442
Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-3 trial G. Pedrazzini, E. Santoro, R. Latini, L. Fromm, M. G. Franzosi, T. Mocetti, L. Staszewsky, S. Barlera, G. Tognoni and A. P. Maggioni *Am Heart J* (2008) 155; 388-94
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18215613
Effect of beta blockers (metoprolol or propranolol) on effect of simvastatin in lowering C-reactive protein in acute myocardial infarction J. C. Quinaglia e Silva, D. B. Munhoz, T. N. Morato, A. Gurgel, A. C. Macedo, P. Sever and A. C. Sposito *Am J Cardiol* (2009) 103; 461-3
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19195502
Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event R. Rawlings, A. Nohria, P. Y. Liu, J. Donnelly, M. A. Creager, P. Ganz, A. Selwyn and J. K. Liao *Am J Cardiol* (2009) 103; 437-41
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19195498
Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance J. F. Ruisinger, J. M. Backes, C. A. Gibson and P. M. Moriarty *Am J Cardiol* (2009) 103; 393-4
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19166695
A 6 month randomized, double blind, placebo controlled, multi-center trial of high dose atorvastatin on myocardial perfusion abnormalities by positron emission tomography in coronary artery disease S. Sdringola, K. L. Gould, L. G. Zamarka, R. McLain and J. Garner *Am Heart J* (2008) 155; 245-53

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18215593

Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel J. M. Siller-Matula, A. O. Spiel, I. M. Lang, G. Kreiner, G. Christ and B. Jilma *Am Heart J* (2009) 157; 148 e1-5

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19081411

Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages K. Sugamura, S. Sugiyama, T. Nozaki, Y. Matsuzawa, Y. Izumiya, K. Miyata, M. Nakayama, K. Kaikita, T. Obata, M. Takeya and H. Ogawa *Circulation* (2009) 119; 28-36

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19103987

Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus ≥65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study) M. J. Tikkanen, I. Holme, N. B. Cater, M. Szarek, O. Faergeman, J. J. Kastelein, A. G. Olsson, M. L. Larsen, C. Lindahl and T. R. Pedersen *Am J Cardiol* (2009) 103; 577-82

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19231315

Cardiovascular disease and risk factors in Asia: a selected review H. Ueshima, A. Sekikawa, K. Miura, T. C. Turin, N. Takashima, Y. Kita, M. Watanabe, A. Kadota, N. Okuda, T. Kadowaki, Y. Nakamura and T. Okamura *Circulation* (2008) 118; 2702-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19106393

Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease Y. R. van Gestel, S. E. Hoeks, D. D. Sin, C. Simsek, G. M. Welten, O. Schouten, H. Stam, F. W. Mertens, R. T. van Domburg and D. Poldermans *Am J Cardiol* (2008) 102; 192-6

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18602520

Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease C. M. Webb, A. G. Elkington, M. M. Kraidly, N. Keenan, D. J. Pennell and P. Collins *Am J Cardiol* (2008) 101; 618-24

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18308009

Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials J. Wlodarczyk, D. Sullivan and M. Smith *Am J Cardiol* (2008) 102; 1654-62

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19064019

B-type natriuretic peptide: a treatment, not a diagnostic marker G. W. Yip *Heart* (2008) 94; 542-4

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation>

n&list_uids=18411344

Collagen-targeting vascular endothelial growth factor improves cardiac performance after myocardial infarction J. Zhang, L. Ding, Y. Zhao, W. Sun, B. Chen, H. Lin, X. Wang, L. Zhang, B. Xu and J. Dai *Circulation* (2009) 119; 1776-84

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19307480